Promising Findings For Breast Cancer Patients Who Respond Well To Neoadjuvant Chemo

Promising Findings For Breast Cancer Patients Who Respond Well To Neoadjuvant Chemo
Neoadjuvant ChemoA new hope for women with breast cancer is being pursued through the development of neoadjuvant chemotherapy. Neoadjuvant therapy is a treatment given to patients before their primary treatment, usually either a mastectomy (removal of one or both breasts) or a lumpectomy (tumor and a small amount of tissue around it is removed). Now, results from a clinical trial involving approximately 12,000 women, presented at the 2014 Breast Cancer Symposium entitled, "Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC)," prompted researchers to hypothesize that women with breast cancer who respond favorably to neoadjuvant chemotherapy might be spared radiotherapy and even be subject to far less extensive surgery. The study's lead investigator Eleftherios Mamounas, MD, MPH noted growing agreement among researchers and clinicians in breast cancer treatment: to choose breast cancer patients who have optimal conditions to go without treatment after surgery. Therefore, identifying independent predictors of recurrence is of the utmost importance. The findings showed that pathologic complete response (pCR) and tumor subtype are "strong predictors" of cancer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.